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Background: Few high penetrance genes are known in Malignant Melanoma (MM), however, the involvement of
low-penetrance genes such as MC1R, OCA2, ASIP, SLC45A2 and TYR has been observed. Lately, genome-wide
association studies (GWAS) have been the ideal strategy to identify new common, low-penetrance susceptibility
loci. In this case–control study, we try to validate in our population nine melanoma associated markers selected
from published GWAS in melanoma predisposition.
Methods: We genotyped the 9 markers corresponding to 8 genes (PARP1, MX2, ATM, CCND1, NADSYN1, CASP8, IRF4
and CYP2R1) in 566 cases and 347 controls from a Spanish population using KASPar probes. Genotypes were
analyzed by logistic regression and adjusted by phenotypic characteristics.
Results: We confirm the protective role in MM of the rs3219090 located on the PARP1 gene (p-value 0.027).
Additionally, this SNP was also associated with eye color (p-value 0.002). A second polymorphism, rs12203592,
located on the IRF4 gene was associated with protection to develop MM for the dominant model (p-value 0.037).
We have also observed an association of this SNP with both lentigines (p-value 0.014) and light eye color (p-value
3.76 × 10−4). Furthermore, we detected a novel association with rs1485993, located on the CCND1 gene, and dark
eye color (p-value 4.96 × 10−4). Finally, rs1801516, located on the ATM gene, showed a trend towards a protective
role in MM similar to the one firstly described in a GWAS study.
Conclusions: To our knowledge, this is the first time that these SNPs have been associated with MM in a Spanish
population. We confirmed the proposed role of rs3219090, located on the PARP1 gene, and rs12203592, located on
the IRF4 gene, as protective to MM along the same lines as have previous genome-wide associated works. Finally,
we have seen associations between IRF4, PARP1, and CCND1 and phenotypic characteristics, confirming previous
results for the IRF4 gene and presenting novel data for the last two, suggesting that pigmentation characteristics
correlated with eye color are potential mediators between PARP1 and MM protection.
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Few malignant melanoma (MM) susceptibility genes have
been described in the literature so far, with only two high-
penetrance genes mutated in 20-40% of familial cases
(Cyclin-dependent kinase inhibitor 2 (CDKN2A) and
Cyclin-dependent kinase 4 (CDK4)) [1-3]. Seems likely that
other genetic factors account for the remaining risk, and
that environment should play a role in the etiology as well.
It has been suggested that the remaining genetic risks may
be due to low-penetrance susceptibility genes, such as the
melanocortin-1 receptor (MC1R) gene. MC1R plays a role
in pigmentation in several species; also, genetic variants are
associated with pigmentary phenotypes in humans, includ-
ing red hair, pale skin, freckling, and sun sensitivity [4,5].
Indeed, MC1R variants are associated with melanoma sus-
ceptibility in several study populations [6-19].
Subsequent studies examined other genes associated with
MM. In population-based studies using candidate-gene ap-
proaches, a solute carrier 45A2 (SLC45A2) variant was as-
sociated with dark hair, dark skin, and protection from
melanoma [20-23]. Variations in one of the genes causing
oculo-albinism syndrome (OCA2) were associated with
melanoma in other studies [24,25], Agouti signaling protein
(ASIP) was found to modify melanoma risk in the presence
of MC1R variants [12], and the Tyrosinase gene (TYR) has
variants which code for skin color and are implicated in
tanning response [26,27].
Recently, new genome-wide association studies (GWAS)
have been conducted and have identified novel genomic
loci associated with melanoma [26,28,29]. GWAS are the
ideal strategy to identify common, low-penetrance suscepti-
bility loci without prior hypotheses about the role of the
genes. Some of the associations detected were already
known, such as MC1R with pigmentation and skin cancer,
ASIP, TYR, OCA2, among others. Several novel chromo-
somal regions, however, have been revealed by using large
cohorts of samples created by meta-analyses across studies,
like 11q22.3 in Ataxia telangiectasia mutated gene (ATM),
21q22.3 located in Myxovirus resistance 2 gene (MX2) and
2q33.1 in Caspase 8 gene (CASP8) [26].
Taking into account that basal pigmentation and sus-
ceptibility to MM differ among populations would be im-
portant for determining the relevance of these new
markers in more darkly pigmented populations such as
the Spanish. Thus, in the present case–control study, we
show the analysis of nine SNPs (corresponding to 8
genes: poly (ADP-ribose) polymerase 1 (PARP1), ATM,
CASP8, MX2, Cyclin D1 (CCND1), cytochrome P450
family 2 subfamily R polypeptide 1 (CYP2R1), NAD syn-
thetase 1 (NADSYN1) and interferon regulatory factor 4
(IRF4). Six of them were detected by several GWAS stud-
ies looking for susceptibility to MM predisposition and
an additional three were related to MM and serum levels
of vitamin D levels which have been recently studied inrelation to sun exposure and their protective role against
cancer and other diseases [30,31].
Methods
Study subjects and data collection
A total of 566 non-related MM sample cases were recruited
from 1st September 2004 up to the present at the depart-
ments of dermatology of three different Hospitals in
Madrid: Gregorio Marañón University General Hospital,
from La Paz University Hospital and Ramón y Cajal Uni-
versity Hospital. A total of 347 volunteer cancer-free con-
trol samples, were recruited at the National Research
Cancer Center (CNIO) the Madrid College of Lawyers and
Gregorio Marañón University General Hospital. All partici-
pants were Caucasians of Spanish origin, with the same
ethnic background [32].
A standardized questionnaire was used to collect in-
formation on pigmentation characteristics such as eye,
hair and skin color, number of nevi, presence of solar
lentigines, sun exposure habits and presence of child-
hood sunburns. Sun exposure data consists of an esti-
mation of the frequency (occasionally, always or never)
of chronic sun exposure (due to daily work outdoors)
and occasional sun exposure (corresponding to spor-
adic, weekend or holiday exposure), plus the use of sun-
screen. Fitzpatrick’s classification of skin type, tumor
localization, Breslow index (deep index) and personal or
family history of cancer was extracted from the medical
record of cases only. (Categorization of these variables
as well as the distribution of the Spanish population
sampled are shown in Additional file 1).
All study subjects gave informed consent, and the study
was approved by the Ethics Committee of the Gregorio
Marañón General University Hospital.
Genomic DNA from cases and controls was isolated
from peripheral blood lymphocytes and diluted to a
final solution of 50 ng/μl using the traditional saline
method or the DNAzol procedure (Invitrogen, Eugene,
OR, USA). DNA concentration was quantified in samples
prior to genotyping by using Quant-iT PicoGreen dsDNA
Reagent (Invitrogen, Eugene, OR, USA). Further concen-
tration measures were obtained using a Nanodrop 2000
spectrophotometer. Genomic DNA was amplified using
the GenomiPhi DNA Amplification Kit (GE Healthcare
Bio-Sciences AB, Uppsala, Sweden).
SNPs selection
Nine SNPs were selected from recent literature using high-
throughput platforms in GWAS in order to validate the
detected markers in a Spanish population (Table 1). Public
databases were used to collect information about SNPs and
genes: NCBI http://www.ncbi.nlm.nih.gov and Ensembl
http://www.ensembl.org. Details such as MIM code, loca-
tion, encoded protein, amino acid changes, nucleotide
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databases and the context sequence are provided in
Additional file 2.
Genotyping assays
Genotyping was carried out using KASPar technology
(KBiosciences, Hoddesdon, UK). The PCR was performed
in a total reaction volume of 4 μl containing about 10 ng of
genomic DNA, with a final concentration of 4X New
KASPar Reaction Mix, 12 μm of each Kaspar primer.
The PCR conditions depended on the requirements of
each probe according to the manufacturer’s indications.
The genotype of each sample was determined by measuring
final allele-specific fluorescence in the ABI Prism 7900HT
Detection System, using the SDS 2.3 software for allelic dis-
crimination (Applied Biosystems, Foster City, USA).
As a quality control measure, we included one no tem-
plate sample and one sample duplicate per 96-well plate (a
total of four per 384-well plate used). Genotypes were pro-
vided automatically by the software and were confirmed
manually by two different personnel in the laboratory.
Statistical analyses
For all polymorphisms studied, Fisher’s exact test was used
both to test for deviations from Hardy-Weinberg equilib-
rium (HWE) among controls, as well as to compare differ-
ences in the minor allele frequency (MAF) distributions
between cases and controls. We set as risk factor the minor
allele detailed in Table 2. We also performed a Cochran-
Armitage trend test for allelic associations using the
complement XLSTAT [33]. Preliminary analyses were
performed using SPSSv19 (SPSS, Chicago, IL, USA). AllTable 1 Previous published genome wide association studies
A) Published studies of association with Melanoma
Study Gene SNP Allele
MacGregor et al. 2011 PARP1 rs3219090 A




Duffy et al. 2010 IRF4 rs12203592 C
B) Previous studies of association with Vitamin D levels
Study Gene SNP Allele
Wang et al. 2011 CYP2R1 rs10741657 A
NADSYN1 rs7944926 A
NADSYN1 rs12785878 G
[VitD] means concentration of vitamin D on plasma.
OR: Odds Ratio.
The allele referes to the one considered as risk allele in the appropriated studies.p-values were two-sided, and those less than 0.05 were con-
sidered statistically significant. In order to assess associa-
tions among genotypes, haplotypes and MM risk, several
analyses were performed. Genotype-related odds ratios
(ORs), their corresponding 95% confidence intervals (CIs)
and associated p-values were estimated via unconditional
logistic regression. This was done for three penetrance
models: genotypic, dominant (major homozygotes versus
heterozygotes plus minor homozygotes) and recessive
(major homozygotes plus heterozygotes versus minor
homozygotes).
Multivariate analysis was carried out combining all sig-
nificant risk factors revealed in Additional file 1, in a
multivariate logistic regression to estimate ORs, 95% CI
and p-values. To assess the association of phenotypic
characteristics with melanoma, the same logistic re-
gression analyses were performed. To assess the media-
tion we performed logistic regression analyses using R
(http://www.R-project.org) [34], based on the indications
given at http://davidakenny.net/cm/mediate.htm. Known
risk factors for MM (eye color, hair color, lentigines, and
childhood sunburns) were evaluated for potential con-
founding effects by including them in multivariate ana-
lyses with each significant associated SNP.
Functional analyses
We used the Haploview v4.2 tool from the HapMap
webpage, in order to analyze linkage disequilibrium blocks
for SNPs in the PARP1 gene in order to know the frequen-
cies of each haplotype in our population and HapMap pop-
ulations from Northern Europe (CEU) and Tuscany Italians
(TSI). We try to asses possible functional implications ofconsidered in the present study
OR p-value MM association
0.82 9.5 × 10-7 Protective
0.79 4.80 × 10-7 Protective
1.18 5.68 × 10-7 Risk
0.85 5.60 × 10-7 Protective
1.19 4.15 × 10-7 Risk
1.15 4 × 10-3 Protective
Published Data
[VitD] < 75 nmol/L levels [VitD] < 50 nmol/L levels
OR (CI 95%) p-value OR (CI 95%) p-value
1.21 (1.45-1.29) 9.4 × 10-11 1.06 (1.00-1.13) 0.06
1.21 (1.14-1.29) 4.1 × 10-10 1.21 (1.14-1.29) 4.7 × 10-9
- - - -
Table 2 Allelic frequencies in Spanish cases and controls
Gene SNP Minor allele p-HWE MAF Controls MAF Cases p-value trend*
PARPI rs3219090 A 0.27 0.329 0.275 0.023 0.028
CASP8 rs13016963 A 0.98 0.414 0.399 0.542 0.561
MX2 rs45430 G 0.93 0.380 0.392 0.624 0.603
CYP2R1 rs10741657 A 0.16 0.378 0.381 0.891 0.867
CCND1 rs1485993 T 0.48 0.448 0.438 0.697 0.652
NADSYN1 rs7944926 A 0.27 0.355 0.333 0.363 0.392
NADSYN1 rs12785878 G 0.75 0.369 0.330 0.102 0.109
ATM rs1801516 A 0.04 0.145 0.121 0.185 0.208
IRF4 rs12203592 T 0.01 0.152 0.148 0.8 0.720
p-HWE: p-value obtained for deviation from Hardy-Weinberg Equilibrium. MAF: Minor Allele Frequency. Bold indicates statistically significant results.
*Trend p-values are obtained by performing a Cochran-Armitage test for trend.
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the online software Pupasuitev3.1 (http://pupasuite.bioinfo.
cipf.es) and the web tool “ECR Browser “(http://ecrbrowser.
dcode.org/) to establish a comparison between the human
genome and those of other animal species in order to
analyze whether gene variations studied in this work are
located in sequences important to the function of the
protein and to search for the phylogenetically conserved
regions of such genes as PARP1, ATM and IRF4 genes.
Results
HWE and Allelic distributions
All polymorphisms were checked for HWE. Allele fre-
quencies for each SNP and p-values for their comparison
between 566 MM cases and 347 individual controls are
detailed in Table 2 along with the p-values for the test
of departure from Hardy-Weinberg equilibrium among
controls. Only two SNPs gave slight departure from
HWE rs1801516 in ATM (p-value 0.04) and rs12203592
in IRF4 (p-value 0.01).
Based on unadjusted p-values, we observed evidence of
differences in allele frequency for the SNP in the PARP1
gene (rs3219090, p-value 0.023), implicated in DNA re-
pair, Cochran-Armitage test support this association with
a p-value of 0.028. We did not observe differences in the
minor allele frequencies between cases and controls for
any other SNP. Data are shown in Table 2.
Association between Genotypes and Melanoma risk
Two SNPs were found to be associated with MM sus-
ceptibility: rs3219090*A, located on the PARP1 gene and
implicated in cell repair, is associated with protection
from MM using the genotypic model with OR 0.79, 95%
CI 0.63-0.97; p-value 0.027, and rs12203592*T, located
in the IRF4 gene, implicated in the immune response,
which is associated with MM risk, when the recessive
model is considered with OR 6.28, 95% CI 1.45-27.13;
p-value 0.014. Due to the small number of minor allele
homozygotes forming the risk group in the recessivemodel, we assumed this could be a spurious association.
The same allele rs12203592*T also shows a trend to-
wards protection when considering the dominant model
with OR 0.83, 95% CI 0.61-1.12; p-value 0.2. The SNP
rs12785878*G on the NADSYN1 gene, associated previ-
ously with Vitamin D levels in plasma [31], is borderline
associated with MM susceptibility when dominant
model is taken into account, with OR 0.76, 95% CI 0.57-
1.02; p-value 0.065.
Finally, allele rs1801516*A, located on the ATM gene,
shows a trend towards protection in a similar manner to
the published data in the GWAS previously reported
[26] (Table 1). We were not, however, able to obtain sta-
tistically significant results (p-value 0.2). No other asso-
ciation remained statistically significant for any of the
studied SNPs. Data is shown in Table 3 and in Table 4.
We performed a multivariate analysis, taking into ac-
count phenotypic risk factors such as eye and hair color,
solar lentigines and the presence of childhood sunburn,
together with candidate SNPs. We verified that hair
color, lentigines and childhood sunburn were independ-
ently associated with MM. Our SNP most associated
with MM protection, rs3219090, maintained the trend
(OR 0.82, CI 95% 0.62-1.07; p-value 0.15). Since this
SNP was associated with eye color, a risk factor for MM,
we suspected that the association between rs3219090
and MM was actually mediated by the eye color. In
order to test for the mediation effect of eye color, we
performed a mediation analysis considering as covariates
the SNP as well as the eye color. The association be-
tween this gene and melanoma was no longer significant
after adjustment for eye color (OR 0.81, CI 95% 0.65-
1.01, p-value 0.066). For the rs12203592 SNP located on
the IRF4 gene, we observed a statistically significant re-
sult (OR 0.65 CI 95% 0.44-0.98, p-value 0.037) for the
dominant model, reinforcing the trend towards pro-
tection found in the non-adjusted analysis. The SNP
rs12785878 on the NADSYN1 gene maintained a trend
to signification. See adjusted values on Table 4.
Table 3 Genotypic analyses of all the SNPs studied and their association with MM susceptibility in Spanish population
Gene SNP Controls N (%) Cases N (%) Association
Major homozygotes Heterozygotes Minor homozygotes Major homozygotes Heterozygotes Minor homozygotes OR (CI 95%) p-value
PARP1 rs3219090 149 (46.4) 133 (41.4) 39 (12.1) 255 (53.2) 184 (38.4) 40 (8.3) 0.79 (0.63-0.97) 0.027
ATM rs1801516 232 (74.6) 68 (21.0) 11 (3.5) 349 (77.7) 91 (20.3) 9 (2) 0.83 (0.62-1.11) 0.203
CASP8 rs13016963 112 (34.3) 158 (48.5) 56 (17.2) 174 (35.5) 241 (49.2) 75 (15.3) 0.94 (0.77-1.15) 0.539
MX2 rs45430 123 (38.3) 152 (47.3) 46 (14.3) 180 (37.6) 221 (46.2) 77 (16.1) 1.05 (0.86-1.29) 0.627
CCND1 rs1485993 93 (29.5) 162 (51.4) 60 (19.1) 143 (30.7) 237 (51) 85 (18.3) 0.96 (0.78-1.18) 0.691
IRF4 rs12203592 242 (70.1) 101 (29.3) 2 (0.6) 398 (74) 121 (22.5) 19 (3.5) 0.97 (0.74-1.26) 0.801
CYP2R1 rs10741657 123 (40.6) 131 (43.2) 49 (16.2) 172 (38.1) 214 (47.4) 65 (14.4) 1.01 (0.82-1.25) 0.893
NADSYN1 rs7944926 138 (43) 138 (43) 45 (14) 210 (45.5) 195 (42.3) 56 (12.1) 0.91 (0.74-1.12) 0.380
NADSYN1 rs12785878 130 (39.3) 157 (47.4) 44 (13.3) 211 (45.9) 194 (42.2) 55 (11.9) 0.84 (0.68-1.04) 0.106
Bold indicates statistically significant results.
N refers to the count of individuals, percentages among the total are indicated between parentheses.
OR (CI95%) means Odds Ratio and its 95% Confidence Interval.


















Table 4 MM associated SNPs with statistically significant associations in any of the three penetrance models analysed
Gene SNP Penetrance model
Non adjusted Adjusted
OR (CI 95%) p-value OR (CI 95%) p-value
PARP1 rs3219090 Codominant GG/AG/AA 0.79 (0.63-0.97) 0.027 0.82 (0.62-1.07) 0.151
Dominant GG/AG + AA 0.76 (0.57-1.01) 0.059 0.80 (0.56-1.15) 0.228
Recessive GG + AG/AA 0.66 (0.41-1.05) 0.079 0.7 (0.38-1.28) 0.246
IRF4 rs12203592 Codominant CC/CT/TT 0.97 (0.74-1.26) 0.801 0.76 (0.53-1.08) 0.122
Dominant CC/CT + TT 0.83 (0.61- 1.12) 0.214 0.65 (0.44-0.98) 0.037
Recessive CC + CT/TT 6.28 (1.45-27.13) 0.014 4.07 (0.83-20.05) 0.084
NADSYN1 rs12785878 Codominant TT/GT/GG 0.84 (0.68-1.04) 0.106 0.83 (0.64-1.08) 0.165
Dominant TT/GT + GG 0.76 (0.57-1.02) 0.065 0.76 (0.53-1.10) 0.142
Recessive TT + GT/GG 0.89 (0.58-1.35) 0.575 0.84 (0.49-1.44) 0.522
ATM rs1801516 Codominant GG/AG/AA 0.83 (0.62-1.11) 0.203 0.88 (0.61-1.28) 0.504
Dominant GG/AG + AA 0.84 (0.6-1.18) 0.318 0.92 (0.59-1.41) 0.686
Recessive GG + AG/AA 0.56 (0.23-1.36) 0.198 0.53 (0.15-1.8) 0.310
Bold indicates statistically significant results.
OR (CI 95%) means Odds Ratio and its 95% Confidence Interval.
The results are obtained taking into account three penetrance models: Codominant (major homozygotes versus heterozygotes versus minor homozygotes),
Dominant (major homozygotes versus heterozygotes plus minor homozygotes) and Recessive (major homozygotes plus heterozygotes versus
minor homozygotes).
Adjusted for eye color, hair color, lentigines and childhood sunburn via multivariate analysis by performing logistic regression.
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characteristics
We assessed whether the SNPs selected from GWAs
studies were associated with various phenotypic charac-
teristics. To carry out this task we used the genotypic,
dominant and recessive models for each SNP and their
associations with all phenotypes.
We observed strong evidence of association with eye
color for 3 SNPs. Two of them, rs3219090 on the PARP1
gene with OR: 0.69 (CI 95%: 0.54-0.88, p-value 0.002),
and rs1485993 on the CCND1 gene with OR 0.561 (CI
95% 0.41-0.78, p-value 4.96 × 10−4), both correlated with
dark eye color. The third, rs12203592 on the IRF4 gene,
with OR 1.83 (CI 95% 1.34-2.51, p-value 1.63 × 10−4)
was associated with light eye color.
The rs12203592 SNP on the IRF4 gene with OR 1.61
(CI 95% 1.16-2.24, p-value 0.005) is correlated with the
presence of lentigines. We observed an association with
absence of childhood sunburn with the SNP rs12785878
located on the NADSYN1 gene with OR 0.69 (CI 95%
0.51-0.93, p-value 0.015).
We observed other less robust phenotype correlations
for skin color and two SNPs; rs10741657 on the CYP2R1
gene with OR 1.24 (CI 95% 1-1.54, p-value 0.045) and
rs7944926 on the NADSYN1 gene with OR 1.37 (CI 95%
1.03-1.84, p-value 0.033) were both associated with light
skin color. Additionally, we observed two SNPs associ-
ated with the number of nevi: rs7944926 on the
NADSYN1 gene with an OR of 1.59 (CI 95% 1.01-2.48,
p-value 0.044) and the rs1801516 on the ATM gene with
an OR of 3.12 (CI 95% 1.06-9.21, p-value 0.039). All this
data is shown in Additional file 3.Functional and haplotype analysis and association with
melanoma risk
We have previous results for rs1136410 on the PARP1
gene [35], and we have combined them with the current
results for rs3219090 on the same gene. We performed
haplotype analyses; both SNPs belong to a single block
according to the Haploview v4.2 program (data used
from HAPMAP_CEU and TSI subset of samples). Three
haplotypes were obtained, with “TG” being the majority
haplotype at 70% frequency. When we studied the case–
control analysis, a trend towards protection for the
haplotype “CA”, with the homozygotes minor alleles in
both positions, is maintained (OR 0.79). Furthermore,
we detected that two SNPs at approximately 8 kb in the
5’upstream region of the ATG, (rs224984 and rs139755)
are in complete LD with the associated rs3219090.
When we checked for transcription binding sites in the
surrounding sequences of these two SNPs, we observed
a likely probability for the presence of the regulatory
gene functions of interest. Finally, the functional assess-
ment for the 34 genetic variants in the whole sequence
of the PARP1 gene showed a single LD block, and 18
of the SNPs present might be located in phylogene-
tic conserved regions. Only the minor allele of a non-
synonymous variant (rs1136410, pV762A) is carried in
approximately half the haplotypes that carry our geno-
typed SNP. The results of these analyses indicate that SNP
rs3219090 is located in a simple repeats area in intron 13,
close to an exon. This region is conserved in the cow (bos
taurus), macacus (rhesus macaque) and chimpanzee (pan
troglodytes). It acts as an intronic enhancer and might
function as a regulator of transcription factors.
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intron 4, and this region is conserved in the opossum
(monodelphis domestica), rat (rattus norvegicus), mouse
(mus musculus), dog (canis familiaris), cow (bos taurus),
macacus (rhesus macaque) and chimpanzee (pan troglo-
dytes). When studying the complete genomic region of
the IRF4 gene, we observed 25 SNPs of which 18 are lo-
cated in conserved regions, including the genotyped
rs12203592; however, only the rs1514346 SNP located in
the putative promoter region are not in LD with the ge-
notyped SNP in this study appears to affect the binding
to the TFBS ETS1.
The rs1801516 SNP, located on the ATM gene, is located
in exon 34 and may disrupt splicing regulation. This SNP is
conserved in opossum (monodelphis domestica), rat (rattus
norvegicus), mouse (mus musculus), dog (canis familiaris),
cow (bos taurus), macacus (rhesus macaque) and chimpan-
zee (pan troglodytes). When we studied the whole genetic
variability of the gene, we observed 12 out of 62 SNPs of a
non-synonymous nature, among which was the genotyped
rs1801516*A, responsible for the change at position 1853
of the protein that causes an alteration of the common
amino acid Asp [D] (negative charge) to a polar residue,
Asn [N]. Furthermore, another 35 SNPs seem to be located
in conserved regions.
Discussion
In this case–control study we have analyzed a group of nine
SNPs selected from previous GWAS and literature related
with MM and/or Vitamin D levels with the intention of val-
idating the results in a Spanish population. These validation
studies are important in order to confirm the role of these
SNPs in populations with different levels of basic pigmenta-
tion and make them more relevant. The study in our popu-
lation, one from the southern Mediterranean, allowed us to
observe two strong associations. Despite being able to de-
tect pigmentation and MM associations with some of the
candidates, we could not validate them all, probably due to
our modest sample size which may not be sufficiently large
enough to detect associations from GWAS which use thou-
sands of samples. It is worth noting that having data on sun
exposure habits and phenotypic traits has allowed us to give
robustness to our results. In addition, we have been able to
find novel pigmentation associations and validate others
previously described, thereby providing relevant comple-
ment information.
First of all, we would like to highlight the rs3219090 SNP,
which is located in intron 13 on the PARP1 gene. This gene
codes for a chromatin-associated enzyme, poly-ADP
ribosyltransferase, which is implicated in several important
cell functions such as DNA repair. PARP1 was studied pre-
viously in relation to melanoma [35,36]; however, the
rs3219090 was firstly detected in a GWAS study [28], and
the validation of its protective role to MM predispositionhas been confirmed in this study’s southern Mediterranean
(Spanish) population (p-value 0.027). Furthermore, we ob-
served a novel association with eye color (p-value 0.002)
not described elsewhere for rs3219090*A. The melanoma
association does not remain significant after performing
mediation test with eye color, suggesting that this phe-
notypic trait could mediate to melanoma susceptibility in
this population. Nevertheless, our data maintained the
same trend towards protection previously described in the
GWAS [29]. Additional functional assessments performed
in the current study have shown that the associated SNP
could indeed be located in an important region since it is a
conserved sequence in mammalian species. Furthermore,
two SNPs in complete LD with rs3219090, and which are
close to the starting codon, could disrupt the binding sites
of several transcription factors. This gene has been related
to other diseases like gastric cancer [37], cardiopathies [38],
glioblastoma [39], bladder cancer [40] and breast cancer
[41]. This association to MM could be very relevant. For
example, in a highly drug resistant cancer such as melan-
oma, a candidate gene with known and available inhibitors
could be used as an effective therapy, as is being studied in
other cancers [42]. Moreover, mechanisms such as gene si-
lencing can reduce the aggressiveness of MM, further
suggesting that this gene may be a possible candidate for
future therapy [43].
Second, we confirmed a protective association with
rs12203592, located in intron 4 on the IRF4 gene. This
gene codes for a protein which belongs to the family of
transcription factors. The IRFs are important in the
regulation of interferon in response to viral infections,
and in the regulation of interferon-inducible genes. This
SNP was firstly detected in GWAs with an association
for hair color and skin pigmentation [44], followed by an
association with tanning phenotype [45]. In spite of its
being related to pigmentation, the association of this
rs12203592 with MM was not always detected [46]. In
our study, rs12203592*T was associated with protection
to melanoma (OR 0.65, p-value 0.037) when dominant
penetrance model is taken into account. A recently pub-
lished study suggests that minor allele of this SNP
(rs12203592*T) is actually associated with risk of devel-
oping skin cancer, including MM [47], nevertheless our
study validates the protective association obtained by
Duffy et al., where rs12203592*C (major allele) was asso-
ciated with the presence of nevi and a predisposition to
melanoma [48]. Although we have not being able to find
any association between the presence of nevi and
rs12203592, we did detect an association with lentigines
[48]. In addition, we obtained a strong correlation with
light eye color and this SNP (p-value 1.63 *10−4). This
result points in the same direction as previous works in
which this SNP has been associated with human skin
and eyes pigmentation and was selected as one of the six
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in order to predict eye color) [49]. This SNP was slightly
out of HWE (p-value 0.01); however, other SNPs located
on pigmentation genes such as SLC45A2 alleles, have
shown deviation from HWE in several populations of
Caucasian origin. This may be explained by the effects
of natural selection on skin color, assortative mating or
admixture [21,50]. The region around this SNP is con-
served in all mammalian species sequenced to date.
There are known associations between the IRF4 gene
and several diseases, such as rhinitis [51] and chronic
lymphocytic leukemia [52,53].
Similarly, we have detected for the first time an associ-
ation with dark eye color and rs1485993*T located on the
CCND1 gene (p-value 4.96 × 10−4). Although six SNPs are
used in a multiplex that identifies blue vs non-blue eyes,
with high correlation and forensic applications, it is of inter-
est to further analyze this proposed SNP due to the strong
association found in our study.
Finally, we would like to highlight that the SNP
(rs1801516) located on another gene with repair functions,
ATM, shows an interesting trend towards a protective role
in MM similar to the one described in the first GWAS
study [26]. In addition, the SNP is in a region with high se-
quence conservation for all mammalian species available so
far. Moreover, according to an in silico functional analysis
performed, it may well be able to regulate several transcrip-
tion factors. The protein encoded by this gene belongs to
the PI3/PI4-kinase family. This protein is an important cell
cycle checkpoint kinase, and the closely related kinase ATR
are thought to be master controllers of the cell cycle check-
point signaling pathways required for cell response to DNA
damage and for genome stability. As well as being respon-
sible for Ataxia telangiectasia, ATM is also involved in sev-
eral diseases such as diabetes mellitus type 2 [54], leukemia
[55], breast cancer [56] and cervix cancer [57], in which the
rs1801516 SNP, has been associated with the risk to de-
velop LSIL (Low grade Squamous Intraepithelial Lesion).
Moreover, therapeutic advances have been described, based
on ATM inhibitors, which are capable of inducing cell
apoptosis in cancer cell killing in Melanoma cases [58]. The
fact that PARP1 and ATM genes are involved in cell repair,
suggests that DNA repair signaling pathways are an import-
ant function in susceptibility to melanoma risk.Conclusions
In summary, we detected two associations with MM,
rs3219090 on the PARP1 gene (mediated by eye color), and
rs12203592, on the IRF4 gene (significant after adjusted by
phenotypic traits), both conferring a protective role in MM.
In addition, we detected three associations the pigmentary
characteristics such as eye color, for PARP1, IRF4 and
CCND1 genes in our study population.Additional files
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